Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | FASN | P49327 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28364250 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TSHRFASNLMNAHSD17B10 | |
| SCHEMBL14837512 | 0.81 | FASN (0.46) | ALDH1A1TSHRFASNLMNAHSD17B10 | |
| Alcohol SCHEMBL346159 | 0.80 | ALDH1A1 (0.55) | ALDH1A1TSHRFASNFAAHKDM4E | |
| SCHEMBL11263700 | 0.80 | FASN (0.38) | ALDH1A1TSHRFASNLMNAHSD17B10 | |
| SCHEMBL11263702 | 0.80 | FASN (0.38) | ALDH1A1TSHRFASNLMNAHSD17B10 | |
| SCHEMBL11578926 | 0.80 | FASN (0.38) | ALDH1A1TSHRFASNLMNAHSD17B10 | |
| SCHEMBL23067640 | 0.79 | LMNA (0.36) | ALDH1A1TSHRLMNAHSD17B10MEN1 | |
| SCHEMBL16294296 | 0.79 | LMNA (0.36) | ALDH1A1TSHRLMNAHSD17B10MEN1 | |
| SCHEMBL16294497 | 0.79 | LMNA (0.36) | ALDH1A1TSHRLMNAHSD17B10MEN1 | |
| SCHEMBL16295229 | 0.79 | LMNA (0.36) | ALDH1A1TSHRLMNAHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9364454-B2 | Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20130150446-A1 | ANTI-INFLAMMATORY ACTIONS OF NEUROPROTECTIN D1/PROTECTIN D1 AND ITS NATURAL STEREOISOMERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-06-13 | — | — | US | disclosed |
| US-8273792-B2 | Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-20090156673-A1 | ANTI-INFLAMMATORY ACTIONS OF NEUROPROTECTIN D1/PROTECTIN D1 AND IT'S NATURAL STEREOISOMERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. CORPORATE SPONSORED RESEARCH & LICENSING (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2007041440-A2 | ANTI-INFLAMMATORY ACTIONS OF NEUROPROTECTIN D1/PROTECTIN D1 AND ITS NATURAL STEREOISOMERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150446-A1 | ANTI-INFLAMMATORY ACTIONS OF NEUROPROTECTIN D1/PROTECTIN D1 AND ITS NATURAL STEREOISOMERS | PTGER1, PTGES, PTGS1 | ALDH1A1 1172/4885TSHR 3888/4885FASN 42/4885 |
| US-20090156673-A1 | ANTI-INFLAMMATORY ACTIONS OF NEUROPROTECTIN D1/PROTECTIN D1 AND IT'S NATURAL STEREOISOMERS | ALOX15, ALOX12, ALOX15B | ALDH1A1 302/4885TSHR 3515/4885FASN 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.